Developer docs
API playgroundTry for free, no card

Search company profiles

Edelris

Full company profile

uuid000gzub

Namestring
Edelris
Legal namestring
Edelris
Websiteurl
edelris.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Edelris is a privately held French drug discovery contract research organization (CRO) founded in 2005 and headquartered in Lyon, France. The company provides compound libraries, medicinal chemistry, high-throughput screening, and analytical chemistry services to pharmaceutical, biotech, cosmetic, and crop protection clients, with a particular focus on small molecule drug discovery against challenging target classes. Following its 2024 integration with Janvier Group Biosciences, Edelris operates as part of a diversified group while maintaining its Lyon-based scientific operations.

The company's technical differentiation centers on the proprietary Keymical Space™, a curated collection of more than 2 million physical and approximately 50 million virtual sp3-rich, 3D-shaped, natural product-inspired screening compounds, supplemented by 153,000 natural product-inspired fragments, 800+ covalent compounds, and EdelREADY screening plates. These libraries are combined with Affinity Selection-Mass Spectrometry (AS-MS) screening through the proprietary EDEN™ platform (Edelris Discovery ENgine) to deliver validated hits on difficult targets including GPCRs, protein-protein interfaces, transcription factors, and RNA targets, with an end-to-end AS-MS turnaround of approximately 4 months. Edelris has pioneered E3-ligase biased library development since 2017 (originating from a collaboration with Craig Crews at Yale) and offers specialized differential and immobilized AS-MS methodologies for molecular glue and PROTAC discovery.

Edelris operates a fee-for-service business model with quote-based engagements tailored to client project requirements, delivering services through dedicated business development personnel including a Chief Business Officer. The company has produced documented outcomes including BAY-850 (Bayer's ATAD2 probe, IC50=22nM), nanomolar Cyclophilin D inhibitors for EMD Serono, CD10847 Caspase-1 inhibitor (IC50=17nM) for Galderma, and contributed to the clinical-stage asset Vonafexor with Poxel. Named enterprise clients include Bayer HealthCare, EMD Serono, Galderma, AstraZeneca, and Cedilla Therapeutics, alongside long-term collaborations with the European Lead Factory and academic partners at the University of Leeds and Technical University of Denmark.

Short descriptiontext

Edelris is a Lyon-based French drug discovery CRO providing proprietary natural product-inspired compound libraries (Keymical Space™), AS-MS screening (EDEN™), medicinal chemistry, and analytical services to pharmaceutical, biotech, cosmetic, and crop protection clients globally, with specialized capabilities in induced-proximity drug discovery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medicinal chemistry, drug discovery services, contract research, compound screening, chemical libraries
Industry1 code
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Other Scientific and Technical Consulting Services541690
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Drug Discovery Contract Research (CRO)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services (CRO)
TypeProfessional Services
Description

Edelris generates revenue through fee-for-service contract research engagements providing drug discovery services including screening, compound libraries, medicinal chemistry, custom synthesis, and analytical chemistry to pharmaceutical, biotech, cosmetic, and crop protection clients.

edelris.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1EDEN (Edelris Discovery ENgine)
Description

Platform combining Affinity Selection-Mass Spectrometry screening with multimillion compound proprietary Keymical Space for discovering novel hits

edelris.com
+6 more records
Core offering1 text field

Edelris is a medicinal chemistry contract research organization that delivers integrated drug discovery services to pharmaceutical, biotechnology, cosmetics, and crop-protection clients. Its core offering combines a proprietary Affinity Selection Mass Spectrometry screening platform (EDEN) with curated compound collections (Keymical Space, Keymical Fragments, Covalent Keymical Collections, DNA-encoded libraries), medicinal chemistry for hit-to-lead and lead optimization, custom synthesis, and analytical chemistry.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • BAY-850 identified as potent (IC50=22nM), selective, cell-active isoform-selective ATAD2 chemical probe with unprecedented mode of action for Bayer HealthCare
+5 more records
Product overview1 text field

Edelris is a leading Drug Discovery CRO providing a comprehensive suite of services and proprietary products for small molecule drug discovery. The core offerings include Screening technologies (AS-MS via the EDEN platform), Compound collections (Keymical Collections including Covalent, Fragment, EdelREADY, and DNA-encoded libraries), Medicinal chemistry (Hit-to-Lead and Lead Optimization), Custom synthesis & Route scouting, and Analytical chemistry. The company has developed a differentiated technology platform centered on its proprietary Keymical Space (2M+ screening compounds, 50M virtual structures) combined with AS-MS screening capabilities. Additionally, Edelris offers specialized Induced-Proximity Drug Discovery services for PROTACs and molecular glue degraders, with dedicated AS-MS screening methodologies including Differential AS-MS and Immobilized AS-MS for molecular glue discovery. Services are delivered to Pharmaceutical, Cosmetic, Crop Protection, and Biotech sectors.

Product and service9 records
1EDEN Affinity Selection Mass Spectrometry (AS-MS) Screening
CategoryCompound screening service
Description

Proprietary label-free, immobilization-free AS-MS screening service that identifies compounds binding to protein targets; offered as a contract screening service to pharmaceutical, biotechnology, cosmetics, and crop-protection R&D teams.

2Keymical Space Screening Collections
CategoryCompound library / reagent collection
Description

Proprietary, curated, and diversified compound screening library used within Edelris's AS-MS and medicinal chemistry services; available to clients screening against their targets.

3Keymical Fragments Library
CategoryCompound library / reagent collection
Description

Proprietary fragment-based screening collection for fragment-based drug discovery, offered as part of Edelris's screening and chemistry services.

4Covalent Keymical Collections
CategoryCompound library / reagent collection
Description

Proprietary covalent screening library designed to identify covalently binding compounds against client targets, delivered as a screening service.

5DNA-Encoded Libraries (DEL)
CategoryCompound screening service
Description

DNA-encoded library screening service enabling ultra-large library screening against client targets, complementing the EDEN AS-MS platform.

6Medicinal Chemistry Services
CategoryMedicinal chemistry service
Description

Integrated medicinal chemistry for hit-to-lead and lead optimization, including structure-activity relationship (SAR) studies and analog synthesis for pharma, biotech, cosmetics, and crop-protection programs.

7Custom Synthesis
CategoryCustom synthesis service
Description

Custom chemical synthesis of client-specified molecules and analogs to support drug discovery and crop-protection / cosmetics research programs.

8Analytical Chemistry Services
CategoryAnalytical chemistry service
Description

Analytical chemistry support for screening, synthesis, and medicinal chemistry campaigns, including characterization of compounds generated for clients.

9Induction-Proximity Drug Discovery
CategoryDrug discovery service
Description

Differentiated drug discovery modality offered by Edelris that exploits induction-proximity mechanisms for novel target modulation, delivered as a contract research service.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Craig Crews (Yale University)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Edelris began pioneering E3-ligase-biased library development in 2017 through an initial collaboration with Craig Crews at Yale. This foundational partnership established Edelris' expertise in targeted protein degradation and E3-ligase biased library design.

edelris.com
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

AstraZeneca co-hosts the 6th Edelris Annual Symposium on AS-MS in Drug Discovery at The Discovery Centre (DISC), Cambridge, UK in September 2026. The collaboration represents a strategic industry partnership for scientific networking and technology promotion in the AS-MS field.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Edelris is a key contributor to the European Lead Factory, a pan-European collaborative platform of 30 partners (pharma companies, SMEs, and academic centers) working to build a 500,000-compound screening collection. Edelris collaborated with University of Leeds (Profs Nelson and Marsden) and Technical University of Denmark (Profs Clausen and Nielsen) to establish a platform delivering 10,000 molecules yearly, achieving 40,000 sp3-rich compounds over 5 years. Edelris published 11 articles related to this project.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner collaborating with Edelris on the European Lead Factory project, contributing to the design and synthesis of innovative scaffold-based compound libraries.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner collaborating with Edelris on the European Lead Factory project, contributing expertise in chemical synthesis and library design alongside Profs Clausen and Nielsen.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborated with Edelris on the FUI-funded NATHEB project for the development of Vonafexor, an FXR agonist for hepatitis B treatment.

7Janvier Group
Strategic tierFlagshipTypeOthers
Description

Edelris was integrated with the global Janvier Group Biosciences in 2024. Jean-Yves Ortholand served as CEO from 2005 to 2022 and then as Chief Business and Strategy Officer from 2022-2024. The integration represents a significant corporate structure change.

edelris.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Sponsor of the 2024 and 2025 Edelris AS-MS Symposium events.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Sponsor of the 2025 Edelris AS-MS Symposium (6th edition).

10Beckman Coulter
Strategic tierMinorTypeGTM or Marketing Partner
Description

Sponsor of the 2025 Edelris AS-MS Symposium (6th edition).

edelris.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Discovery arm of Eurofins Scientific offering compound libraries, in vitro pharmacology, and medicinal chemistry services. Broader portfolio than Edelris but with overlapping screening and chemistry offerings to similar pharma/biotech buyers.

TypeDirect peer
Description

Hamburg-based integrated drug discovery CRO offering medicinal chemistry, screening, and induced-proximity services. Closest comparable to Edelris in business model, customer base (pharma/biotech), and end-to-end discovery offering, but at much larger scale.

TypeDirect peer
Description

Canada-based medicinal chemistry CRO focused on small molecule drug discovery for biotech and pharma. Comparable boutique CRO scale and customer overlap, with similar fee-for-service chemistry engagement model.

TypeEmerging player
Description

Switzerland-based specialty chemistry CRO with expertise in 3D-rich, sp3-rich compound synthesis and parallel chemistry. Smaller and more narrowly focused than Edelris but conceptually adjacent on natural-product-inspired chemical matter.

TypeDirect peer
Description

Poland-headquartered CRO offering medicinal chemistry, in vitro pharmacology, and integrated drug discovery. Comparable in scale and breadth to Edelris, with overlapping pharma/biotech client base and similar fee-for-service CRO economics.

TypeDirect peer
Description

UK-based drug discovery CRO of similar size and focus, providing medicinal chemistry, DMPK, and in vitro biology services to pharma and biotech. Comparable specialty-CRO model with a similar European footprint and enterprise pharma client base.

TypeBroad incumbent
Description

China-headquartered global CRO/CDMO with extensive medicinal chemistry and discovery capabilities. Competes with Edelris for outsourced pharma chemistry work but at vastly greater scale and broader service breadth.

TypeDirect peer
Description

UK-based integrated drug discovery CRO with services spanning medicinal chemistry, assay development, and computational chemistry. Comparable boutique CRO profile with similar pharma/biotech client base.

TypeBroad incumbent
Description

Large global CRO offering discovery, safety assessment, and manufacturing services. Overlaps with Edelris in medicinal chemistry and in vitro discovery but operates at dramatically larger scale across multiple service lines.

TypeDirect peer
Description

US-based CRO offering medicinal chemistry, in vitro pharmacology, and screening services. Comparable specialty CRO with overlapping biotech/pharma client base and discovery-focused offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Edelris

Drug Discovery Contract Research (CRO)edelris.com

Edelris is a Lyon-based French drug discovery CRO providing proprietary natural product-inspired compound libraries (Keymical Space™), AS-MS screening (EDEN™), medicinal chemistry, and analytical services to pharmaceutical, biotech, cosmetic, and crop protection clients globally, with specialized capabilities in induced-proximity drug discovery.

What Edelris does

Edelris is a privately held French drug discovery contract research organization (CRO) founded in 2005 and headquartered in Lyon, France. The company provides compound libraries, medicinal chemistry, high-throughput screening, and analytical chemistry services to pharmaceutical, biotech, cosmetic, and crop protection clients, with a particular focus on small molecule drug discovery against challenging target classes. Following its 2024 integration with Janvier Group Biosciences, Edelris operates as part of a diversified group while maintaining its Lyon-based scientific operations.

The company's technical differentiation centers on the proprietary Keymical Space™, a curated collection of more than 2 million physical and approximately 50 million virtual sp3-rich, 3D-shaped, natural product-inspired screening compounds, supplemented by 153,000 natural product-inspired fragments, 800+ covalent compounds, and EdelREADY screening plates. These libraries are combined with Affinity Selection-Mass Spectrometry (AS-MS) screening through the proprietary EDEN™ platform (Edelris Discovery ENgine) to deliver validated hits on difficult targets including GPCRs, protein-protein interfaces, transcription factors, and RNA targets, with an end-to-end AS-MS turnaround of approximately 4 months. Edelris has pioneered E3-ligase biased library development since 2017 (originating from a collaboration with Craig Crews at Yale) and offers specialized differential and immobilized AS-MS methodologies for molecular glue and PROTAC discovery.

Edelris operates a fee-for-service business model with quote-based engagements tailored to client project requirements, delivering services through dedicated business development personnel including a Chief Business Officer. The company has produced documented outcomes including BAY-850 (Bayer's ATAD2 probe, IC50=22nM), nanomolar Cyclophilin D inhibitors for EMD Serono, CD10847 Caspase-1 inhibitor (IC50=17nM) for Galderma, and contributed to the clinical-stage asset Vonafexor with Poxel. Named enterprise clients include Bayer HealthCare, EMD Serono, Galderma, AstraZeneca, and Cedilla Therapeutics, alongside long-term collaborations with the European Lead Factory and academic partners at the University of Leeds and Technical University of Denmark.

Edelris firmographics

Firmographics
Name
Edelris
Legal name
Edelris
Website
https://edelris.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
Edelris is a Lyon-based French drug discovery CRO providing proprietary natural product-inspired compound libraries (Keymical Space™), AS-MS screening (EDEN™), medicinal chemistry, and analytical services to pharmaceutical, biotech, cosmetic, and crop protection clients globally, with specialized capabilities in induced-proximity drug discovery.
Ownership category
akta.pro rank

Edelris industry classification

Industry
Product category
Drug Discovery Contract Research (CRO)
NAICS
Other Scientific and Technical Consulting Services (541690)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Medicinal chemistry
  • Drug discovery services
  • Contract research
  • Compound screening
  • Chemical libraries

Where Edelris is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Edelris business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services (CRO): Edelris generates revenue through fee-for-service contract research engagements providing drug discovery services including screening, compound libraries, medicinal chemistry, custom synthesis, and analytical chemistry to pharmaceutical, biotech, cosmetic, and crop protection clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Edelris product offering

Product offering

Core offering

Edelris is a medicinal chemistry contract research organization that delivers integrated drug discovery services to pharmaceutical, biotechnology, cosmetics, and crop-protection clients. Its core offering combines a proprietary Affinity Selection Mass Spectrometry screening platform (EDEN) with curated compound collections (Keymical Space, Keymical Fragments, Covalent Keymical Collections, DNA-encoded libraries), medicinal chemistry for hit-to-lead and lead optimization, custom synthesis, and analytical chemistry.

Product overview

Edelris is a leading Drug Discovery CRO providing a comprehensive suite of services and proprietary products for small molecule drug discovery. The core offerings include Screening technologies (AS-MS via the EDEN platform), Compound collections (Keymical Collections including Covalent, Fragment, EdelREADY, and DNA-encoded libraries), Medicinal chemistry (Hit-to-Lead and Lead Optimization), Custom synthesis & Route scouting, and Analytical chemistry. The company has developed a differentiated technology platform centered on its proprietary Keymical Space (2M+ screening compounds, 50M virtual structures) combined with AS-MS screening capabilities. Additionally, Edelris offers specialized Induced-Proximity Drug Discovery services for PROTACs and molecular glue degraders, with dedicated AS-MS screening methodologies including Differential AS-MS and Immobilized AS-MS for molecular glue discovery. Services are delivered to Pharmaceutical, Cosmetic, Crop Protection, and Biotech sectors.

Differentiator

Problem solved

Functional benefit

Brands

  • EDEN (Edelris Discovery ENgine): Platform combining Affinity Selection-Mass Spectrometry screening with multimillion compound proprietary Keymical Space for discovering novel hits
  • Keymical Collections
  • Keymical Space
  • Keymical Fragments
  • EdelREADY
  • Covalent Keymical Collections
  • European Lead Factory

Products and services

  • EDEN Affinity Selection Mass Spectrometry (AS-MS) Screening Proprietary label-free, immobilization-free AS-MS screening service that identifies compounds binding to protein targets; offered as a contract screening service to pharmaceutical, biotechnology, cosmetics, and crop-protection R&D teams.
  • Keymical Space Screening Collections Proprietary, curated, and diversified compound screening library used within Edelris's AS-MS and medicinal chemistry services; available to clients screening against their targets.
  • Keymical Fragments Library Proprietary fragment-based screening collection for fragment-based drug discovery, offered as part of Edelris's screening and chemistry services.
  • Covalent Keymical Collections Proprietary covalent screening library designed to identify covalently binding compounds against client targets, delivered as a screening service.
  • DNA-Encoded Libraries (DEL) DNA-encoded library screening service enabling ultra-large library screening against client targets, complementing the EDEN AS-MS platform.
  • Medicinal Chemistry Services Integrated medicinal chemistry for hit-to-lead and lead optimization, including structure-activity relationship (SAR) studies and analog synthesis for pharma, biotech, cosmetics, and crop-protection programs.
  • Custom Synthesis Custom chemical synthesis of client-specified molecules and analogs to support drug discovery and crop-protection / cosmetics research programs.
  • Analytical Chemistry Services Analytical chemistry support for screening, synthesis, and medicinal chemistry campaigns, including characterization of compounds generated for clients.
  • Induction-Proximity Drug Discovery Differentiated drug discovery modality offered by Edelris that exploits induction-proximity mechanisms for novel target modulation, delivered as a contract research service.

Quantifiable outcome

  • BAY-850 identified as potent (IC50=22nM), selective, cell-active isoform-selective ATAD2 chemical probe with unprecedented mode of action for Bayer HealthCare
  • +5 more outcomes

Companies that use Edelris

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles2 records

Edelris technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Edelris partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

  • Craig Crews (Yale University)coreStrategic or Co-development Partner · 1 January 2017Edelris began pioneering E3-ligase-biased library development in 2017 through an initial collaboration with Craig Crews at Yale. This foundational partnership established Edelris' expertise in targeted protein degradation and E3-ligase biased library design.
  • AstraZenecaflagshipStrategic or Co-development PartnerAstraZeneca co-hosts the 6th Edelris Annual Symposium on AS-MS in Drug Discovery at The Discovery Centre (DISC), Cambridge, UK in September 2026. The collaboration represents a strategic industry partnership for scientific networking and technology promotion in the AS-MS field.
  • European Lead FactorycoreStrategic or Co-development PartnerEdelris is a key contributor to the European Lead Factory, a pan-European collaborative platform of 30 partners (pharma companies, SMEs, and academic centers) working to build a 500,000-compound screening collection. Edelris collaborated with University of Leeds (Profs Nelson and Marsden) and Technical University of Denmark (Profs Clausen and Nielsen) to establish a platform delivering 10,000 molecules yearly, achieving 40,000 sp3-rich compounds over 5 years. Edelris published 11 articles related to this project.
  • University of LeedscoreStrategic or Co-development PartnerAcademic partner collaborating with Edelris on the European Lead Factory project, contributing to the design and synthesis of innovative scaffold-based compound libraries.
  • Technical University of DenmarkcoreStrategic or Co-development PartnerAcademic partner collaborating with Edelris on the European Lead Factory project, contributing expertise in chemical synthesis and library design alongside Profs Clausen and Nielsen.
  • INSERMminorStrategic or Co-development PartnerCollaborated with Edelris on the FUI-funded NATHEB project for the development of Vonafexor, an FXR agonist for hepatitis B treatment.
  • Janvier GroupflagshipOthersEdelris was integrated with the global Janvier Group Biosciences in 2024. Jean-Yves Ortholand served as CEO from 2005 to 2022 and then as Chief Business and Strategy Officer from 2022-2024. The integration represents a significant corporate structure change.
  • Mestrelab ResearchminorGTM or Marketing PartnerSponsor of the 2024 and 2025 Edelris AS-MS Symposium events.
  • HamiltonminorGTM or Marketing PartnerSponsor of the 2025 Edelris AS-MS Symposium (6th edition).
  • Beckman CoulterminorGTM or Marketing PartnerSponsor of the 2025 Edelris AS-MS Symposium (6th edition).

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Edelris competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Discovery: Discovery arm of Eurofins Scientific offering compound libraries, in vitro pharmacology, and medicinal chemistry services. Broader portfolio than Edelris but with overlapping screening and chemistry offerings to similar pharma/biotech buyers.
  • WuXi AppTec: China-headquartered global CRO/CDMO with extensive medicinal chemistry and discovery capabilities. Competes with Edelris for outsourced pharma chemistry work but at vastly greater scale and broader service breadth.
  • Charles River Laboratories: Large global CRO offering discovery, safety assessment, and manufacturing services. Overlaps with Edelris in medicinal chemistry and in vitro discovery but operates at dramatically larger scale across multiple service lines.

Direct peers

  • Evotec: Hamburg-based integrated drug discovery CRO offering medicinal chemistry, screening, and induced-proximity services. Closest comparable to Edelris in business model, customer base (pharma/biotech), and end-to-end discovery offering, but at much larger scale.
  • NuChem Therapeutics: Canada-based medicinal chemistry CRO focused on small molecule drug discovery for biotech and pharma. Comparable boutique CRO scale and customer overlap, with similar fee-for-service chemistry engagement model.
  • Selvita: Poland-headquartered CRO offering medicinal chemistry, in vitro pharmacology, and integrated drug discovery. Comparable in scale and breadth to Edelris, with overlapping pharma/biotech client base and similar fee-for-service CRO economics.
  • Sygnature Discovery: UK-based drug discovery CRO of similar size and focus, providing medicinal chemistry, DMPK, and in vitro biology services to pharma and biotech. Comparable specialty-CRO model with a similar European footprint and enterprise pharma client base.
  • Domainex: UK-based integrated drug discovery CRO with services spanning medicinal chemistry, assay development, and computational chemistry. Comparable boutique CRO profile with similar pharma/biotech client base.
  • Reaction Biology: US-based CRO offering medicinal chemistry, in vitro pharmacology, and screening services. Comparable specialty CRO with overlapping biotech/pharma client base and discovery-focused offering.

Emerging players

  • SpiroChem: Switzerland-based specialty chemistry CRO with expertise in 3D-rich, sp3-rich compound synthesis and parallel chemistry. Smaller and more narrowly focused than Edelris but conceptually adjacent on natural-product-inspired chemical matter.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Edelris social profiles

Digital presence

Edelris financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Edelris leadership team

Management profile

Number of profiles

Profiles4 records

Edelris funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Edelris M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Edelris

What does Edelris do?

Edelris is a medicinal chemistry contract research organization that delivers integrated drug discovery services to pharmaceutical, biotechnology, cosmetics, and crop-protection clients. Its core offering combines a proprietary Affinity Selection Mass Spectrometry screening platform (EDEN) with curated compound collections (Keymical Space, Keymical Fragments, Covalent Keymical Collections, DNA-encoded libraries), medicinal chemistry for hit-to-lead and lead optimization, custom synthesis, and analytical chemistry.

Is Edelris a public or private company?

Edelris is a private company. It is classified as corporate owned and is currently operating.

When was Edelris founded?

Edelris was founded in 2005. It employs 51 to 100 people.

Where is Edelris based?

Edelris is headquartered in Lyon, France, in the Europe region.

How does Edelris make money?

One revenue line is on record: contract Research Services (CRO).

Who are Edelris's main competitors?

Broad incumbents on record are Eurofins Discovery, WuXi AppTec and Charles River Laboratories. Direct peers are Evotec, NuChem Therapeutics, Selvita, Sygnature Discovery, Domainex and Reaction Biology. SpiroChem is listed as an emerging player.

Does Edelris have an API?

No public API is recorded for Edelris.

What industry is Edelris in?

Edelris's product category is Drug Discovery Contract Research (CRO). Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541690 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales